Findings

What do systematic reviews say?

34 questions · 35 findings · 17 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 10 · 28.6%GRADE not reported 3 · 8.6%Very low 5 · 14.3%Low 8 · 22.9%Moderate 8 · 22.9%High 1 · 2.9%

Quinolone vs macrolides

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Macrolides vs tetracycline

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Quinolone vs tetracycline

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Protocol using standard measures such as CVP vs usual care

All‐cause mortality · patients with perioperative fluid optimization

Protocol using standard measures such as CVP showed no clear difference in all‐cause mortality compared with usual care (low certainty).

1 finding from 1 review

Perioperative fluid volume optimization following proximal femoral fracture 2016 · Cochrane Headline outcomes only
RR 2.81 [0.61, 12.81]
1 study · 60 participants
Low

Advanced haemodynamic monitoring vs usual care

All‐cause mortality · patients with perioperative fluid optimization

Advanced haemodynamic monitoring showed no clear difference in all‐cause mortality compared with usual care (low certainty).

1 finding from 1 review

Perioperative fluid volume optimization following proximal femoral fracture 2016 · Cochrane Headline outcomes only
RR 0.45 [0.07, 2.95]
3 studies · 213 participants
Low

Intervention not reported

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Extended prophylaxis vs another VTE extended prophylaxis

All‐cause mortalitye · patients with unprovoked venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Extended prophylaxis vs placebo

All‐cause mortalityg · patients with unprovoked venous thromboembolism

Extended prophylaxis showed no clear difference in all‐cause mortalityg compared with placebo (moderate certainty).

1 finding from 1 review

Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with… 2017 · Cochrane Headline outcomes only
OR 1 [0.63, 1.57]
5 studies · 2043 participants
Moderate

Aspirin vs direct oral anticoagulants (DOAC)

All‐cause mortality ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents

The review found no eligible studies for this question.

1 finding from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolide+tetracycline vs macrolides

All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease

It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1.63 [0.38, 7.02]
1 study · 198 participants
Very low